VES/TIS News

Vestis Corp and Nuvation Bio Post Strong Q2 Results With EBITDA Surges and Raised Guidance

Vestis Corp EBITDA surged 23% and raised FCF guidance; Nuvation Bio's IBTROZI captured ROS1-positive lung cancer leadership with $31.7M revenue and $661M cash.

Aug 18, 2026